Fundamental Data for CRXL

Crucell N.V. discovers, develops, and produces a variety of biopharmaceuticals for the treatment of human diseases. Unlike the technologies generally employed in the biopharmaceutical industry, the company''s technologies are fully-human and, as such, enable biopharmaceuticals to be developed and produced that do not have the limitations inherent in many biopharmaceuticals currently available.

# Employees: 182

Address: Archimedesweg 4-6 PO Box 2048,Leiden,,NLD

Phone: 31 71 524 8701

Fax: 31 71 524 8702

Website: www.crucell.com

Email: ir(at)crucell.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Ronald Brus (Chmn.; Presi.; C.E.O.)

Jean-Yves Guichoux (Exec. V.P.; Devept.)

Arthur Lahr (V.P.; bus. Devept.)

Leonard Kruimer (C.F.O.)

Jaap Goudsmit (Chief Scientific Off.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/4/2010

Mean EPS (Next Qtr): $0.22

Mean EPS (Year): $0.47

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): 45.470

Number of Estimates: 3

Shares Performance

Period	CRXL	Compare to S&P
YTD	41.06 %	16.73 %
4 Weeks	8.20 %	2.72 %
12 Weeks	-3.22 %	-9.87 %

Shares Information

Analyst Coverage: Y

Avg Volume: 116879

Shares Outstanding: 66M

Market Cap: $1.42B

52 Week High: $25.38

52 Week Low: $12.42

P/E Ratio: 38.160

PEG Ratio: -0.010

Split: On 1/1/1990 CRXL split by factor of 0.010

Earnings Performance

EPS Growth in Last Quarter: 650.00 %

EPS Growth in Last Year: -24.14 %

Sales Growth in Last Quarter: 41.13 %

Sales Growth in Last Quarter: 12.51 %

Financials

Qtr Book Value: $1.39

Cash Flow/Share: $22.29

Change in Payout Ratio: 0.000

Price/Sales: 3.090